Short Interest in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Increases By 173.1%

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM – Get Rating) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 1,440,000 shares, a growth of 173.1% from the April 30th total of 527,200 shares. Based on an average daily volume of 2,870,000 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bellicum Pharmaceuticals stock. Susquehanna International Group LLP raised its holdings in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM – Get Rating) by 42.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,310 shares of the biopharmaceutical company’s stock after acquiring an additional 12,616 shares during the quarter. Susquehanna International Group LLP owned approximately 0.49% of Bellicum Pharmaceuticals worth $30,000 as of its most recent filing with the SEC. Institutional investors own 28.66% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. StockNews.com assumed coverage on Bellicum Pharmaceuticals in a report on Wednesday. They issued a “sell” rating on the stock. LADENBURG THALM/SH SH downgraded Bellicum Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, March 15th.

Bellicum Pharmaceuticals Price Performance

Shares of BLCM stock traded up $0.02 on Friday, hitting $0.78. The stock had a trading volume of 93,739 shares, compared to its average volume of 1,871,540. Bellicum Pharmaceuticals has a 1 year low of $0.23 and a 1 year high of $1.55. The company’s 50 day moving average price is $0.48 and its 200-day moving average price is $0.81.

Bellicum Pharmaceuticals Company Profile

(Get Rating)

Bellicum Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.